# Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia

> **NCT05906914** · PHASE2 · COMPLETED · sponsor: **First Affiliated Hospital of Zhejiang University** · enrollment: 65 (actual)

## Conditions studied

- Acute Myeloid Leukemia, Adult

## Interventions

- **DRUG:** cladribine + homoharringtonine + cytarabine

## Key facts

- **NCT ID:** NCT05906914
- **Lead sponsor:** First Affiliated Hospital of Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-26
- **Primary completion:** 2025-04-11
- **Final completion:** 2025-10-31
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2026-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05906914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05906914, "Cladribine Plus Homoharringtonine and Cytarabine Regimen (CHA) for de Novo Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05906914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*